- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT06172296
- Originalversuch
Dinutuximab mit Chemotherapie, Operation und Stammzelltransplantation zur Behandlung von Kindern mit neu diagnostiziertem Hochrisiko-Neuroblastom
Eine Phase-3-Studie mit Dinutuximab als Ergänzung zur intensiven multimodalen Therapie für Kinder mit neu diagnostiziertem Hochrisiko-Neuroblastom
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
- Arzneimittel: Carboplatin
- Arzneimittel: Cyclophosphamide
- Arzneimittel: Cisplatin
- Verfahren: Bone Marrow Biopsy
- Arzneimittel: Doxorubicin
- Arzneimittel: Vincristine
- Verfahren: Magnetic Resonance Imaging
- Verfahren: Echocardiography Test
- Verfahren: Multigated Acquisition Scan
- Verfahren: Bone Marrow Aspiration
- Arzneimittel: Etoposide
- Verfahren: Computed Tomography
- Arzneimittel: Topotecan
- Strahlung: Radiation Therapy
- Verfahren: Biospecimen Collection
- Sonstiges: Survey Administration
- Arzneimittel: Melphalan
- Arzneimittel: Irinotecan
- Arzneimittel: Thiotepa
- Biologisch: Dinutuximab
- Verfahren: FDG-Positron Emission Tomography and Computed Tomography Scan
- Verfahren: Hematopoietic Cell Transplantation
- Arzneimittel: Isotretinoin
- Verfahren: Leukapheresis
- Verfahren: Radionuclide Imaging
- Arzneimittel: Temozolomide
- Verfahren: Tumor Resection
Detaillierte Beschreibung
PRIMARY OBJECTIVE:
I. To determine if the event-free survival (EFS) of patients with newly diagnosed high-risk neuroblastoma assigned to early chemoimmunotherapy during Induction differs from that of patients who are not assigned to treatment that includes early chemoimmunotherapy.
SECONDARY OBJECTIVES:
I. To determine if early chemoimmunotherapy during Induction therapy improves end of Induction (EOI) response rates and overall survival (OS) for patients with newly diagnosed high-risk neuroblastoma.
II. To determine response rates, EFS, and OS following an Extended Induction regimen with chemoimmunotherapy in patients with progressive disease or a poor response to Induction therapy.
III. To compare the toxicities experienced by patients treated with chemoimmunotherapy during Induction versus those experienced by patients treated with standard Induction and to describe toxicities experienced during Extended Induction.
IV. To determine GD2 expression on tumor tissue and tumor cells in bone marrow and assess for associations with response and outcome.
EXPLORATORY OBJECTIVES:
I. To describe the association between tumor and host factors and outcomes in patients receiving protocol therapy.
II. To evaluate circulating biomarkers and markers of minimal residual disease at baseline and during therapy, and assess for associations with response and outcome.
III. To compare patterns of failure between patients treated with and without dinutuximab during induction.
IV. To determine the effect of telomere maintenance mechanisms on end of Induction response rates, EFS, and OS.
V. To explore the impact of high-risk neuroblastoma (HRNBL) and its therapy, including the addition of dinutuximab to Induction chemotherapy, on functional and quality of life outcomes in patients with HRNBL, as measured by caregiver (parent/legal guardian) and patient questionnaires.
VI. To describe the adequacy of diagnostic biopsy specimens, including those obtained by percutaneous core needle biopsy.
VII. To explore the associations between family-reported adverse social determinants of health and both clinical outcomes and biology.
VIII. To develop and validate deep learning predictors of Induction response based on diagnostic MIBG scans. (Imaging Objective) IX. To compare institutional versus central determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and poor end of induction response (PEIR) and good end of induction response (GEIR) determination. (Imaging Objective) X. To describe late toxicities (including impaired organ function, neuropsychiatric toxicity, and incidence of secondary malignancy) in patients treated with dinutuximab during Induction or Extended Induction to late toxicities in patients who have not received dinutuximab during these phases of therapy.
XI. To evaluate whether reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts.
XII. To compare post-transplant complications between treatment arms, and assess for associations with outcome.
XIII. To assess for associations between EOI response (including good end of Induction response [GEIR] and poor end of Induction response [PEIR]) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS).
XIV. To describe and compare the changes in image-defined risk factors (IDRFs) between patients treated with and without dinutuximab during Induction and associate with surgical outcomes and local failure rates following primary tumor resection.
XV. To bank serial samples of blood, bone marrow, and tumor tissue for future research.
OUTLINE: Patients receive Induction cycle 1 and are then randomized to 1 of 2 treatment arms.
INDUCTION CYCLE 1: Patients receive cyclophosphamide intravenously (IV) over 30 minutes and topotecan IV over 30 minutes on days 1-5 in the absence of unacceptable toxicity.
ARM A:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes and topotecan IV over 30 minutes on days 1-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients then receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide orally (PO), via nasogastric tube (NG), or via gastric tube (G-tube) on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous hematopoietic stem cell transplantations (HSCTs) during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion, patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2. Patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO twice daily (BID) on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, echocardiogram (ECHO) or multigated acquisition scan (MUGA), bone marrow aspiration and/or biopsy, computed tomography (CT) scan, magnetic resonance imaging (MRI), iodine-123 meta-iodobenzylguanidine (I-MIBG) scan and possible fluorodeoxyglucose position emission tomography (FDG-PET) scan throughout the study.
ARM B:
INDUCTION CYCLES 2-5: Patients receive cyclophosphamide IV over 30 minutes, topotecan IV over 30 minutes on days 1-5, and dinutuximab IV over 10 hours on days 2-5 of cycle 2 in the absence of unacceptable toxicity. Patients then undergo stem cell harvest via apheresis. Patients receive cisplatin IV over 4 hours and etoposide IV over 2 hours on days 1-3 and dinutuximab IV over 10 hours on days 2-5 of cycles 3 and 5, and vincristine IV on day 1, doxorubicin IV over 15 minutes, and cyclophosphamide IV over 1 hour on days 1-2, and dinutuximab IV over 10 hours on days 2-5 of cycle 4 in the absence of unacceptable toxicity. Patients undergo primary tumor resection after Induction cycle 4 or 5. Following Induction cycle 5, patients undergo testing to determine response to Induction therapy. Patients with a good tumor response proceed to Consolidation, while patients with a poor tumor response proceed to Extended Induction.
EXTENDED INDUCTION: Patients with a poor tumor response or progression during Induction receive temozolomide PO, via NG tube, or via G-tube on days 1-5, irinotecan IV over 90 minutes on days 1-5, and dinutuximab IV over 10 hours. Treatment repeats every 21 days for up to a maximum of 6 cycles in the absence of disease progression or unacceptable toxicity. If at any time during Extended Induction testing shows a good tumor response, patients proceed to Consolidation. If after 6 cycles of Extended Induction or if at any time progression is noted, patients are removed from the study.
CONSOLIDATION: Patients undergo two autologous HSCTs during Consolidation. Patients receive thiotepa IV over 2 hours on days -7 to -5 and cyclophosphamide IV over 1 hour on days -5 to -2 during HSCT 1. Patients then receive stem cell infusion IV on day 0. Between 6 and 10 weeks after stem cell infusion patients receive melphalan IV over 30 minutes on days -7 to -5, etoposide IV over 24 hours on days -7 to -4, and carboplatin over 24 hours on days -7 to -4 during HSCT 2. Patients receive stem cell infusion IV on day 0. Between day +42 and day +80 after HSCT 2, patients receive radiation daily for 12 treatments in the absence of disease progression or unacceptable toxicity.
POST CONSOLIDATION: Patients receive dinutuximab IV over 10 hours on days 4-7 and isotretinoin PO BID on days 11-24 of cycles 1-5. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. Patients then receive isotretinoin PO BID on days 15-28 for 1 additional cycle, cycle 6.
Patients undergo blood and urine sample collection, ECHO or MUGA, bone marrow aspiration and/or biopsy, CT scan, MRI, I-MIBG scan and possible FDG-PET scan throughout the study.
After completion of study treatment, patients are followed up at 3, 6, 9,12, 15, 18, 24, 30, 36, 42, 48, 54, and 60 months and then periodically for up to 10 years from enrollment.
Studientyp
Einschreibung (Geschätzt)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
New South Wales
-
Randwick, New South Wales, Australien, 2031
- Rekrutierung
- Sydney Children's Hospital
-
Hauptermittler:
- Draga Barbaric
-
Kontakt:
- Site Public Contact
- Telefonnummer: (02) 9382-1721
-
Westmead, New South Wales, Australien, 2145
- Rekrutierung
- The Children's Hospital at Westmead
-
Kontakt:
- Site Public Contact
- Telefonnummer: 61-2-9845 1400
-
Hauptermittler:
- Bhavna Padhye
-
-
Queensland
-
South Brisbane, Queensland, Australien, 4101
- Rekrutierung
- Queensland Children's Hospital
-
Hauptermittler:
- Steven A. Foresto
-
Kontakt:
- Site Public Contact
- Telefonnummer: 61 7 3068 1111
-
-
Victoria
-
Parkville, Victoria, Australien, 3052
- Rekrutierung
- Royal Children's Hospital
-
Hauptermittler:
- Martin A. Campbell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 61 3 9345 5656
- E-Mail: Jordan.Hansford@rch.org.au
-
-
Western Australia
-
Perth, Western Australia, Australien, 6009
- Rekrutierung
- Perth Children's Hospital
-
Kontakt:
- Site Public Contact
- E-Mail: helpdesk@childrensoncologygroup.org
-
Hauptermittler:
- Michelle Ng
-
-
-
-
-
Québec, Kanada, G1V 4G2
- Rekrutierung
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
Hauptermittler:
- Bruno Michon
-
Kontakt:
- Site Public Contact
- Telefonnummer: 418-525-4444
- E-Mail: rechclinique@crchudequebec.ulaval.ca
-
-
Alberta
-
Calgary, Alberta, Kanada, T3B 6A8
- Rekrutierung
- Alberta Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 403-220-6898
- E-Mail: research4kids@ucalgary.ca
-
Hauptermittler:
- Victor A. Lewis
-
Edmonton, Alberta, Kanada, T6G 2B7
- Rekrutierung
- University of Alberta Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 780-407-8798
- E-Mail: pedsoncologyresearch@ahs.ca
-
Hauptermittler:
- Sarah J. McKillop
-
-
British Columbia
-
Vancouver, British Columbia, Kanada, V6H 3V4
- Rekrutierung
- British Columbia Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 6477 604-875-2345
-
Hauptermittler:
- Rebecca J. Deyell
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada, R3E 0V9
- Rekrutierung
- CancerCare Manitoba
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-561-1026
- E-Mail: ctu_web@cancercare.mb.ca
-
Hauptermittler:
- Stephanie M. Villeneuve
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, Kanada, A1B 3V6
- Rekrutierung
- Janeway Child Health Centre
-
Hauptermittler:
- Lisa A. Goodyear
-
Kontakt:
- Site Public Contact
- Telefonnummer: 709-777-8727
- E-Mail: beverlyj.mitchell@easternhealth.ca
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada, B3K 6R8
- Rekrutierung
- IWK Health Centre
-
Kontakt:
- Site Public Contact
- Telefonnummer: 902-470-8520
- E-Mail: Research@iwk.nshealth.ca
-
Hauptermittler:
- Chelsea Ash
-
-
Ontario
-
Hamilton, Ontario, Kanada, L8N 3Z5
- Rekrutierung
- McMaster Children's Hospital at Hamilton Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 905-521-2100
-
Hauptermittler:
- Uma H. Athale
-
London, Ontario, Kanada, N6A 5W9
- Rekrutierung
- Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 519-685-8306
-
Hauptermittler:
- Shayna M. Zelcer
-
Ottawa, Ontario, Kanada, K1H 8L1
- Rekrutierung
- Children's Hospital of Eastern Ontario
-
Kontakt:
- Site Public Contact
- Telefonnummer: 613-737-7600
-
Hauptermittler:
- Donna L. Johnston
-
Toronto, Ontario, Kanada, M5G 1X8
- Rekrutierung
- Hospital for Sick Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 416-813-7654
- E-Mail: ask.CRS@sickkids.ca
-
Hauptermittler:
- Daniel A. Morgenstern
-
-
Quebec
-
Montreal, Quebec, Kanada, H3H 1P3
- Rekrutierung
- The Montreal Children's Hospital of the MUHC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-412-4445
- E-Mail: info@thechildren.com
-
Hauptermittler:
- Stephanie Mourad
-
Montreal, Quebec, Kanada, H3T 1C5
- Rekrutierung
- Centre Hospitalier Universitaire Sainte-Justine
-
Hauptermittler:
- Monia Marzouki
-
Kontakt:
- Site Public Contact
- Telefonnummer: 514-345-4931
- E-Mail: yvan.samson@umontreal.ca
-
Sherbrooke, Quebec, Kanada, J1H 5N4
- Rekrutierung
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
Kontakt:
- Site Public Contact
- Telefonnummer: 819-820-6480
- E-Mail: crcinformation.chus@ssss.gouv.qc.ca
-
Hauptermittler:
- Stephanie Vairy
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Kanada, S7N 0W8
- Rekrutierung
- Jim Pattison Children's Hospital
-
Hauptermittler:
- Kathleen Felton
-
Kontakt:
- Site Public Contact
- Telefonnummer: 306-655-3544
- E-Mail: Jessica.Marien@saskhealthauthority.ca
-
-
-
-
Auckland
-
Grafton, Auckland, Neuseeland, 1145
- Rekrutierung
- Starship Children's Hospital
-
Hauptermittler:
- Andrew C. Wood
-
Kontakt:
- Site Public Contact
- Telefonnummer: 0800 728 436
-
-
-
-
-
San Juan, Puerto Rico, 00926
- Rekrutierung
- University Pediatric Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 787-474-0333
-
Hauptermittler:
- Maria E. Echevarria
-
-
-
-
Alabama
-
Birmingham, Alabama, Vereinigte Staaten, 35233
- Rekrutierung
- Children's Hospital of Alabama
-
Kontakt:
- Site Public Contact
- Telefonnummer: 205-638-9285
- E-Mail: oncologyresearch@peds.uab.edu
-
Hauptermittler:
- Elizabeth D. Alva
-
Mobile, Alabama, Vereinigte Staaten, 36604
- Rekrutierung
- USA Health Strada Patient Care Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-388-8721
-
Hauptermittler:
- Hamayun Imran
-
-
Arizona
-
Mesa, Arizona, Vereinigte Staaten, 85202
- Rekrutierung
- Banner Children's at Desert
-
Kontakt:
- Site Public Contact
- Telefonnummer: 480-412-3100
-
Hauptermittler:
- Joseph C. Torkildson
-
Phoenix, Arizona, Vereinigte Staaten, 85016
- Rekrutierung
- Phoenix Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 602-546-0920
-
Hauptermittler:
- Alok K. Kothari
-
Tucson, Arizona, Vereinigte Staaten, 85719
- Rekrutierung
- Banner University Medical Center - Tucson
-
Kontakt:
- Site Public Contact
- E-Mail: UACC-IIT@uacc.arizona.edu
-
Hauptermittler:
- Monica M. Davini
-
-
Arkansas
-
Little Rock, Arkansas, Vereinigte Staaten, 72202-3591
- Rekrutierung
- Arkansas Children's Hospital
-
Hauptermittler:
- Michael W. Bishop
-
Kontakt:
- Site Public Contact
- Telefonnummer: 501-364-7373
-
-
California
-
Downey, California, Vereinigte Staaten, 90242
- Rekrutierung
- Kaiser Permanente Downey Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 626-564-3455
-
Hauptermittler:
- Robert M. Cooper
-
Duarte, California, Vereinigte Staaten, 91010
- Rekrutierung
- City of Hope Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-826-4673
- E-Mail: becomingapatient@coh.org
-
Hauptermittler:
- Hung C. Tran
-
Loma Linda, California, Vereinigte Staaten, 92354
- Rekrutierung
- Loma Linda University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 909-558-4050
-
Hauptermittler:
- Albert Kheradpour
-
Long Beach, California, Vereinigte Staaten, 90806
- Rekrutierung
- Miller Children's and Women's Hospital Long Beach
-
Kontakt:
- Site Public Contact
- Telefonnummer: 562-933-5600
-
Hauptermittler:
- Jacqueline N. Casillas
-
Los Angeles, California, Vereinigte Staaten, 90027
- Rekrutierung
- Children's Hospital Los Angeles
-
Kontakt:
- Site Public Contact
- Telefonnummer: 323-361-4110
-
Hauptermittler:
- Araz Marachelian
-
Los Angeles, California, Vereinigte Staaten, 90048
- Rekrutierung
- Cedars-Sinai Medical Center
-
Hauptermittler:
- Fataneh (Fae) Majlessipour
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-423-2133
- E-Mail: Cancer.trial.info@cshs.org
-
Los Angeles, California, Vereinigte Staaten, 90095
- Rekrutierung
- Mattel Children's Hospital UCLA
-
Kontakt:
- Site Public Contact
- Telefonnummer: 310-825-6708
-
Hauptermittler:
- Satiro N. De Oliveira
-
Madera, California, Vereinigte Staaten, 93636
- Rekrutierung
- Valley Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 559-353-3000
- E-Mail: Research@valleychildrens.org
-
Hauptermittler:
- Ruetima Titapiwatanakun
-
Oakland, California, Vereinigte Staaten, 94611
- Rekrutierung
- Kaiser Permanente-Oakland
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-642-4691
- E-Mail: Kpoct@kp.org
-
Hauptermittler:
- Aarati V. Rao
-
Oakland, California, Vereinigte Staaten, 94609
- Rekrutierung
- UCSF Benioff Children's Hospital Oakland
-
Hauptermittler:
- Jennifer G. Michlitsch
-
Kontakt:
- Site Public Contact
- Telefonnummer: 510-428-3264
- E-Mail: PedOncRschOAK@ucsf.edu
-
Orange, California, Vereinigte Staaten, 92868
- Rekrutierung
- Children's Hospital of Orange County
-
Kontakt:
- Site Public Contact
- Telefonnummer: 714-509-8646
- E-Mail: oncresearch@choc.org
-
Hauptermittler:
- Elyssa M. Rubin
-
Palo Alto, California, Vereinigte Staaten, 94304
- Rekrutierung
- Lucile Packard Children's Hospital Stanford University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-694-0012
- E-Mail: ccto-office@stanford.edu
-
Hauptermittler:
- Jay Michael S. Balagtas
-
Sacramento, California, Vereinigte Staaten, 95817
- Rekrutierung
- University of California Davis Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 916-734-3089
-
Hauptermittler:
- Marcio H. Malogolowkin
-
Sacramento, California, Vereinigte Staaten, 95816
- Rekrutierung
- Sutter Medical Center Sacramento
-
Kontakt:
- Site Public Contact
- E-Mail: clinicalresearch@sutterhealth.org
-
Hauptermittler:
- Sandra Baril
-
San Diego, California, Vereinigte Staaten, 92123
- Rekrutierung
- Rady Children's Hospital - San Diego
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-966-5934
-
Hauptermittler:
- William D. Roberts
-
San Francisco, California, Vereinigte Staaten, 94158
- Rekrutierung
- UCSF Medical Center-Mission Bay
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-827-3222
- E-Mail: cancertrials@ucsf.edu
-
Hauptermittler:
- Arun A. Rangaswami
-
-
Colorado
-
Aurora, Colorado, Vereinigte Staaten, 80045
- Rekrutierung
- Children's Hospital Colorado
-
Hauptermittler:
- Navin R. Pinto
-
Kontakt:
- Site Public Contact
- Telefonnummer: 303-764-5056
- E-Mail: josh.b.gordon@nsmtp.kp.org
-
-
Connecticut
-
Hartford, Connecticut, Vereinigte Staaten, 06106
- Rekrutierung
- Connecticut Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 860-545-9981
-
Hauptermittler:
- Michael S. Isakoff
-
New Haven, Connecticut, Vereinigte Staaten, 06520
- Rekrutierung
- Yale University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 203-785-5702
- E-Mail: canceranswers@yale.edu
-
Hauptermittler:
- Farzana Pashankar
-
-
Delaware
-
Wilmington, Delaware, Vereinigte Staaten, 19803
- Rekrutierung
- Alfred I duPont Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-Mail: Allison.bruce@nemours.org
-
Hauptermittler:
- Sridhi Patel
-
-
District of Columbia
-
Washington D.C., District of Columbia, Vereinigte Staaten, 20010
- Rekrutierung
- Children's National Medical Center
-
Hauptermittler:
- Jeffrey S. Dome
-
Kontakt:
- Site Public Contact
- Telefonnummer: 202-476-2800
- E-Mail: OncCRC_OnCall@childrensnational.org
-
-
Florida
-
Fort Lauderdale, Florida, Vereinigte Staaten, 33316
- Rekrutierung
- Broward Health Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-Mail: Allison.bruce@nemours.org
-
Hauptermittler:
- Hector M. Rodriguez-Cortes
-
Fort Myers, Florida, Vereinigte Staaten, 33908
- Rekrutierung
- Golisano Children's Hospital of Southwest Florida
-
Kontakt:
- Site Public Contact
- Telefonnummer: 239-343-5333
- E-Mail: molly.arnstrom@leehealth.org
-
Hauptermittler:
- Emad K. Salman
-
Gainesville, Florida, Vereinigte Staaten, 32610
- Rekrutierung
- UF Health Cancer Institute - Gainesville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 352-273-8010
- E-Mail: cancer-center@ufl.edu
-
Hauptermittler:
- Brian Stover
-
Hollywood, Florida, Vereinigte Staaten, 33021
- Rekrutierung
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 954-265-1847
- E-Mail: OHR@mhs.net
-
Hauptermittler:
- Iftikhar Hanif
-
Jacksonville, Florida, Vereinigte Staaten, 32207
- Rekrutierung
- Nemours Children's Clinic-Jacksonville
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-Mail: Allison.bruce@nemours.org
-
Hauptermittler:
- Sridhi Patel
-
Miami, Florida, Vereinigte Staaten, 33155
- Rekrutierung
- Nicklaus Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-624-2778
-
Hauptermittler:
- Ziad A. Khatib
-
Miami, Florida, Vereinigte Staaten, 33136
- Rekrutierung
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 305-243-2647
-
Hauptermittler:
- Meghan McCormick
-
Orlando, Florida, Vereinigte Staaten, 32806
- Rekrutierung
- Arnold Palmer Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 321-841-5357
- E-Mail: Jennifer.spinelli@orlandohealth.com
-
Hauptermittler:
- Zhongbo Hu
-
Orlando, Florida, Vereinigte Staaten, 32827
- Rekrutierung
- Nemours Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 302-651-5572
- E-Mail: Allison.bruce@nemours.org
-
Hauptermittler:
- Sridhi Patel
-
Orlando, Florida, Vereinigte Staaten, 32803
- Rekrutierung
- AdventHealth Orlando
-
Kontakt:
- Site Public Contact
- Telefonnummer: 407-303-2090
- E-Mail: FH.Cancer.Research@flhosp.org
-
Hauptermittler:
- Fouad M. Hajjar
-
St. Petersburg, Florida, Vereinigte Staaten, 33701
- Rekrutierung
- Johns Hopkins All Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 727-767-4784
- E-Mail: Ashley.Repp@jhmi.edu
-
Hauptermittler:
- Jennifer B. Dean
-
West Palm Beach, Florida, Vereinigte Staaten, 33407
- Rekrutierung
- Saint Mary's Medical Center
-
Hauptermittler:
- Matthew D. Ramirez
-
Kontakt:
- Site Public Contact
- Telefonnummer: 561-822-4745
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30329
- Rekrutierung
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
Hauptermittler:
- William T. Cash
-
Kontakt:
- Site Public Contact
- Telefonnummer: 404-785-0232
- E-Mail: Olivia.Floyd@choa.org
-
Savannah, Georgia, Vereinigte Staaten, 31404
- Rekrutierung
- Memorial Health University Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 912-350-7887
- E-Mail: Lorraine.OHara@hcahealthcare.com
-
Hauptermittler:
- James N. Yarnall
-
-
Hawaii
-
Honolulu, Hawaii, Vereinigte Staaten, 96826
- Rekrutierung
- Kapiolani Medical Center for Women and Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 808-983-6090
-
Hauptermittler:
- Wade T. Kyono
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60611
- Rekrutierung
- Lurie Children's Hospital-Chicago
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-880-4562
-
Hauptermittler:
- Elizabeth A. Sokol
-
Chicago, Illinois, Vereinigte Staaten, 60637
- Rekrutierung
- University of Chicago Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 773-702-8222
- E-Mail: cancerclinicaltrials@bsd.uchicago.edu
-
Hauptermittler:
- Ami V. Desai
-
Chicago, Illinois, Vereinigte Staaten, 60612
- Rekrutierung
- University of Illinois
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Hauptermittler:
- Dipti S. Dighe
-
Oak Lawn, Illinois, Vereinigte Staaten, 60453
- Rekrutierung
- Advocate Children's Hospital-Oak Lawn
-
Kontakt:
- Site Public Contact
- Telefonnummer: 847-723-7570
-
Hauptermittler:
- Rebecca E. McFall
-
Park Ridge, Illinois, Vereinigte Staaten, 60068
- Rekrutierung
- Advocate Children's Hospital-Park Ridge
-
Kontakt:
- Site Public Contact
- E-Mail: helpdesk@childrensoncologygroup.org
-
Hauptermittler:
- Rebecca E. McFall
-
Peoria, Illinois, Vereinigte Staaten, 61637
- Rekrutierung
- OSF Children's Hospital of Illinois
-
Hauptermittler:
- Prerna Kumar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 309-624-4945
- E-Mail: ChildrensHospitalofIllinois@osfhealthcare.org
-
Springfield, Illinois, Vereinigte Staaten, 62702
- Rekrutierung
- Southern Illinois University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 217-545-7929
-
Hauptermittler:
- Gregory P. Brandt
-
-
Indiana
-
Indianapolis, Indiana, Vereinigte Staaten, 46202
- Rekrutierung
- Riley Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-248-1199
-
Hauptermittler:
- Marissa Just
-
Indianapolis, Indiana, Vereinigte Staaten, 46260
- Rekrutierung
- Ascension Saint Vincent Indianapolis Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 317-338-2194
- E-Mail: research@stvincent.org
-
Hauptermittler:
- Bassem I. Razzouk
-
-
Iowa
-
Des Moines, Iowa, Vereinigte Staaten, 50309
- Rekrutierung
- Blank Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 515-241-8912
- E-Mail: samantha.mallory@unitypoint.org
-
Hauptermittler:
- Samantha L. Mallory
-
Iowa City, Iowa, Vereinigte Staaten, 52242
- Rekrutierung
- University of Iowa/Holden Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-237-1225
-
Hauptermittler:
- Andrew P. Groves
-
-
Kansas
-
Wichita, Kansas, Vereinigte Staaten, 67214
- Rekrutierung
- Wesley Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 316-962-7802
- E-Mail: WesleyResearch@wesleymc.com
-
Hauptermittler:
- Nathan S. Hall
-
-
Kentucky
-
Lexington, Kentucky, Vereinigte Staaten, 40536
- Rekrutierung
- University of Kentucky/Markey Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
Hauptermittler:
- James T. Badgett
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- Rekrutierung
- Norton Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 502-629-5500
- E-Mail: CancerResource@nortonhealthcare.org
-
Hauptermittler:
- Michael J. Ferguson
-
-
Louisiana
-
New Orleans, Louisiana, Vereinigte Staaten, 70118
- Rekrutierung
- Children's Hospital New Orleans
-
Hauptermittler:
- Maria C. Velez-Yanguas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 504-894-5377
-
-
Maine
-
Bangor, Maine, Vereinigte Staaten, 04401
- Rekrutierung
- Eastern Maine Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-973-4274
-
Hauptermittler:
- Daniel L. Callaway
-
Scarborough, Maine, Vereinigte Staaten, 04074
- Rekrutierung
- Maine Children's Cancer Program
-
Hauptermittler:
- Sei-Gyung K. Sze
-
Kontakt:
- Site Public Contact
- Telefonnummer: 207-396-8670
- E-Mail: clinicalresearch@mainehealth.org
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21287
- Rekrutierung
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
Hauptermittler:
- Allen R. Chen
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-955-8804
- E-Mail: jhcccro@jhmi.edu
-
Baltimore, Maryland, Vereinigte Staaten, 21215
- Rekrutierung
- Sinai Hospital of Baltimore
-
Hauptermittler:
- Jason M. Fixler
-
Kontakt:
- Site Public Contact
- Telefonnummer: 410-601-9083
-
Baltimore, Maryland, Vereinigte Staaten, 21201
- Rekrutierung
- University of Maryland/Greenebaum Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-888-8823
-
Hauptermittler:
- Teresa A. York
-
Bethesda, Maryland, Vereinigte Staaten, 20889-5600
- Rekrutierung
- Walter Reed National Military Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 301-319-2100
-
Hauptermittler:
- Kip R. Hartman
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Rekrutierung
- Massachusetts General Hospital Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-726-5130
-
Hauptermittler:
- Lauren H. Boal
-
Boston, Massachusetts, Vereinigte Staaten, 02215
- Rekrutierung
- Dana-Farber Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-442-3324
-
Hauptermittler:
- Suzanne Shusterman
-
-
Michigan
-
Ann Arbor, Michigan, Vereinigte Staaten, 48109
- Rekrutierung
- C S Mott Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-865-1125
-
Hauptermittler:
- Rajen Mody
-
Detroit, Michigan, Vereinigte Staaten, 48201
- Suspendiert
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Vereinigte Staaten, 49503
- Rekrutierung
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Vereinigte Staaten, 49007
- Rekrutierung
- Bronson Methodist Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 616-391-1230
- E-Mail: crcwm-regulatory@crcwm.org
-
Hauptermittler:
- Kathleen Y. Butler
-
Royal Oak, Michigan, Vereinigte Staaten, 48073
- Rekrutierung
- Corewell Health Children's
-
Kontakt:
- Site Public Contact
- Telefonnummer: 248-551-7695
-
Hauptermittler:
- Marie V. Nelson
-
-
Minnesota
-
Minneapolis, Minnesota, Vereinigte Staaten, 55404
- Rekrutierung
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Hauptermittler:
- Michael K. Richards
-
Kontakt:
- Site Public Contact
- Telefonnummer: 612-813-5913
- E-Mail: pauline.mitby@childrensmn.org
-
Minneapolis, Minnesota, Vereinigte Staaten, 55455
- Rekrutierung
- University of Minnesota/Masonic Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 612-624-2620
-
Hauptermittler:
- Robin L. Williams
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Rekrutierung
- Mayo Clinic in Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 855-776-0015
-
Hauptermittler:
- Peter Schoettler
-
-
Mississippi
-
Jackson, Mississippi, Vereinigte Staaten, 39216
- Rekrutierung
- University of Mississippi Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 601-815-6700
-
Hauptermittler:
- Amanda Strobel
-
-
Missouri
-
Columbia, Missouri, Vereinigte Staaten, 65212
- Rekrutierung
- University of Missouri Children's Hospital
-
Hauptermittler:
- Barbara A. Gruner
-
Kontakt:
- Site Public Contact
- Telefonnummer: 573-882-1960
- E-Mail: snwq62@health.missouri.edu
-
Kansas City, Missouri, Vereinigte Staaten, 64108
- Rekrutierung
- Children's Mercy Hospitals and Clinics
-
Hauptermittler:
- Keith J. August
-
Kontakt:
- Site Public Contact
- Telefonnummer: 816-302-6808
- E-Mail: COGResearchGroup@cmh.edu
-
St Louis, Missouri, Vereinigte Staaten, 63110
- Rekrutierung
- Washington University School of Medicine
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-600-3606
- E-Mail: info@siteman.wustl.edu
-
Hauptermittler:
- Frederick S. Huang
-
St Louis, Missouri, Vereinigte Staaten, 63141
- Rekrutierung
- Mercy Hospital Saint Louis
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-251-7066
-
Hauptermittler:
- Robin D. Hanson
-
-
Nebraska
-
Omaha, Nebraska, Vereinigte Staaten, 68114
- Rekrutierung
- Children's Hospital and Medical Center of Omaha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-955-3949
-
Hauptermittler:
- Jill C. Beck
-
Omaha, Nebraska, Vereinigte Staaten, 68198
- Rekrutierung
- University of Nebraska Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 402-559-6941
- E-Mail: unmcrsa@unmc.edu
-
Hauptermittler:
- Jill C. Beck
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89135
- Rekrutierung
- Alliance for Childhood Diseases/Cure 4 the Kids Foundation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 702-384-0013
- E-Mail: research@sncrf.org
-
Hauptermittler:
- Joseph L. Lasky
-
-
New Hampshire
-
Lebanon, New Hampshire, Vereinigte Staaten, 03756
- Rekrutierung
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Hauptermittler:
- Angela Ricci
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-639-6918
- E-Mail: cancer.research.nurse@dartmouth.edu
-
-
New Jersey
-
Hackensack, New Jersey, Vereinigte Staaten, 07601
- Rekrutierung
- Hackensack University Medical Center
-
Hauptermittler:
- Katharine Offer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 551-996-2897
-
Morristown, New Jersey, Vereinigte Staaten, 07960
- Rekrutierung
- Morristown Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-971-5900
-
Hauptermittler:
- Kathryn L. Laurie
-
New Brunswick, New Jersey, Vereinigte Staaten, 08901
- Rekrutierung
- Saint Peter's University Hospital
-
Hauptermittler:
- Nibal A. Zaghloul
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-745-8600
- E-Mail: officeofresearch@saintpetersuh.com
-
New Brunswick, New Jersey, Vereinigte Staaten, 08903
- Rekrutierung
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 732-235-8675
-
Hauptermittler:
- Nehal S. Parikh
-
Newark, New Jersey, Vereinigte Staaten, 07112
- Rekrutierung
- Newark Beth Israel Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-926-7230
- E-Mail: Christine.Kosmides@rwjbh.org
-
Hauptermittler:
- Teena Bhatla
-
Paterson, New Jersey, Vereinigte Staaten, 07503
- Rekrutierung
- Saint Joseph's Regional Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 973-754-2207
- E-Mail: HallL@sjhmc.org
-
Hauptermittler:
- Alissa Kahn
-
-
New Mexico
-
Albuquerque, New Mexico, Vereinigte Staaten, 87106
- Suspendiert
- University of New Mexico Cancer Center
-
-
New York
-
Albany, New York, Vereinigte Staaten, 12208
- Rekrutierung
- Albany Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 518-262-5513
-
Hauptermittler:
- Lauren R. Weintraub
-
Buffalo, New York, Vereinigte Staaten, 14263
- Rekrutierung
- Roswell Park Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-767-9355
- E-Mail: askroswell@roswellpark.org
-
Hauptermittler:
- Clare J. Twist
-
Mineola, New York, Vereinigte Staaten, 11501
- Rekrutierung
- NYU Langone Hospital - Long Island
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-263-4432
- E-Mail: cancertrials@nyulangone.org
-
Hauptermittler:
- Chana L. Glasser
-
New Hyde Park, New York, Vereinigte Staaten, 11040
- Rekrutierung
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-470-3460
-
Hauptermittler:
- Julie I. Krystal
-
New York, New York, Vereinigte Staaten, 10032
- Rekrutierung
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
Hauptermittler:
- Nobuko Hijiya
-
Kontakt:
- Site Public Contact
- Telefonnummer: 212-342-5162
- E-Mail: cancerclinicaltrials@cumc.columbia.edu
-
New York, New York, Vereinigte Staaten, 10016
- Rekrutierung
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Hauptermittler:
- Elizabeth A. Raetz
-
Kontakt:
- Site Public Contact
- E-Mail: CancerTrials@nyulangone.org
-
Rochester, New York, Vereinigte Staaten, 14642
- Rekrutierung
- University of Rochester
-
Kontakt:
- Site Public Contact
- Telefonnummer: 585-275-5830
-
Hauptermittler:
- Rafi R. Kazi
-
Syracuse, New York, Vereinigte Staaten, 13210
- Rekrutierung
- State University of New York Upstate Medical University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 315-464-5476
-
Hauptermittler:
- Melanie A. Comito
-
The Bronx, New York, Vereinigte Staaten, 10467
- Rekrutierung
- Montefiore Medical Center - Moses Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 718-379-6866
- E-Mail: eskwak@montefiore.org
-
Hauptermittler:
- Alice Lee
-
Valhalla, New York, Vereinigte Staaten, 10595
- Rekrutierung
- New York Medical College
-
Kontakt:
- Site Public Contact
- Telefonnummer: 914-594-3794
-
Hauptermittler:
- Andrew J. Bellantoni
-
-
North Carolina
-
Asheville, North Carolina, Vereinigte Staaten, 28801
- Rekrutierung
- Mission Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 828-213-7055
- E-Mail: NCDV.ResearchRegulatory@HCAHealthcare.com
-
Hauptermittler:
- Douglas J. Scothorn
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- Rekrutierung
- UNC Lineberger Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 877-668-0683
- E-Mail: cancerclinicaltrials@med.unc.edu
-
Hauptermittler:
- Thomas B. Alexander
-
Charlotte, North Carolina, Vereinigte Staaten, 28203
- Rekrutierung
- Carolinas Medical Center/Levine Cancer Institute
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-804-9376
-
Hauptermittler:
- Joel A. Kaplan
-
Charlotte, North Carolina, Vereinigte Staaten, 28204
- Rekrutierung
- Novant Health Presbyterian Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 980-201-6360
- E-Mail: kashah@novanthealth.org
-
Hauptermittler:
- Holly Edington
-
Durham, North Carolina, Vereinigte Staaten, 27710
- Rekrutierung
- Duke University Medical Center
-
Hauptermittler:
- Jessica M. Sun
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-275-3853
-
Greenville, North Carolina, Vereinigte Staaten, 27834
- Rekrutierung
- East Carolina University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 252-744-1015
- E-Mail: eubankss@ecu.edu
-
Hauptermittler:
- Andrea R. Whitfield
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27157
- Rekrutierung
- Wake Forest University Health Sciences
-
Kontakt:
- Site Public Contact
- Telefonnummer: 336-713-6771
-
Hauptermittler:
- Sarah Supples
-
-
North Dakota
-
Fargo, North Dakota, Vereinigte Staaten, 58122
- Rekrutierung
- Sanford Broadway Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 701-323-5760
- E-Mail: OncologyClinicalTrialsFargo@sanfordhealth.org
-
Hauptermittler:
- Samuel J. Milanovich
-
-
Ohio
-
Akron, Ohio, Vereinigte Staaten, 44308
- Rekrutierung
- Children's Hospital Medical Center of Akron
-
Kontakt:
- Site Public Contact
- Telefonnummer: 330-543-3193
-
Hauptermittler:
- Lauren R. Draper
-
Cincinnati, Ohio, Vereinigte Staaten, 45229
- Rekrutierung
- Cincinnati Children's Hospital Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 513-636-2799
- E-Mail: cancer@cchmc.org
-
Hauptermittler:
- Katherine M. Somers
-
Cleveland, Ohio, Vereinigte Staaten, 44195
- Rekrutierung
- Cleveland Clinic Foundation
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-223-8100
- E-Mail: TaussigResearch@ccf.org
-
Hauptermittler:
- Matteo M. Trucco
-
Cleveland, Ohio, Vereinigte Staaten, 44106
- Rekrutierung
- Rainbow Babies and Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 216-844-5437
-
Hauptermittler:
- Duncan S. Stearns
-
Columbus, Ohio, Vereinigte Staaten, 43205
- Rekrutierung
- Nationwide Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 614-722-6039
- E-Mail: Melinda.Triplet@nationwidechildrens.org
-
Hauptermittler:
- Mark A. Ranalli
-
Dayton, Ohio, Vereinigte Staaten, 45404
- Rekrutierung
- Dayton Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-228-4055
-
Hauptermittler:
- Jordan M. Wright
-
Toledo, Ohio, Vereinigte Staaten, 43606
- Rekrutierung
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 419-824-1842
- E-Mail: PCIOncResearch@promedica.org
-
Hauptermittler:
- Jamie L. Dargart
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Vereinigte Staaten, 73104
- Rekrutierung
- University of Oklahoma Health Sciences Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 405-271-8777
- E-Mail: ou-clinical-trials@ouhsc.edu
-
Hauptermittler:
- Rene Y. McNall-Knapp
-
Tulsa, Oklahoma, Vereinigte Staaten, 74136
- Rekrutierung
- Saint Francis Children's Hospital
-
Hauptermittler:
- Jill A. Salo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 918-502-6720
-
-
Oregon
-
Portland, Oregon, Vereinigte Staaten, 97227
- Rekrutierung
- Legacy Emanuel Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-413-2560
-
Hauptermittler:
- Jason M. Glover
-
Portland, Oregon, Vereinigte Staaten, 97239
- Rekrutierung
- Oregon Health and Science University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 503-494-1080
- E-Mail: trials@ohsu.edu
-
Hauptermittler:
- Susan J. Lindemulder
-
-
Pennsylvania
-
Allentown, Pennsylvania, Vereinigte Staaten, 18103
- Rekrutierung
- Lehigh Valley Hospital-Cedar Crest
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-402-9543
- E-Mail: Morgan_M.Horton@lvhn.org
-
Hauptermittler:
- Jacob A. Troutman
-
Danville, Pennsylvania, Vereinigte Staaten, 17822
- Rekrutierung
- Geisinger Medical Center
-
Hauptermittler:
- Jagadeesh Ramdas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 570-271-5251
- E-Mail: cancerresearch@geisinger.edu
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Rekrutierung
- Children's Hospital of Philadelphia
-
Hauptermittler:
- Rochelle Bagatell
-
Kontakt:
- Site Public Contact
- Telefonnummer: 267-425-5544
- E-Mail: CancerTrials@email.chop.edu
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19134
- Rekrutierung
- Saint Christopher's Hospital for Children
-
Kontakt:
- Site Public Contact
- Telefonnummer: 215-427-8991
-
Hauptermittler:
- Gregory E. Halligan
-
Pittsburgh, Pennsylvania, Vereinigte Staaten, 15224
- Rekrutierung
- Children's Hospital of Pittsburgh of UPMC
-
Kontakt:
- Site Public Contact
- Telefonnummer: 412-692-8570
- E-Mail: jean.tersak@chp.edu
-
Hauptermittler:
- Jean M. Tersak
-
-
Rhode Island
-
Providence, Rhode Island, Vereinigte Staaten, 02903
- Rekrutierung
- Rhode Island Hospital
-
Hauptermittler:
- Bradley DeNardo
-
Kontakt:
- Site Public Contact
- Telefonnummer: 401-444-1488
-
-
South Carolina
-
Charleston, South Carolina, Vereinigte Staaten, 29425
- Rekrutierung
- Medical University of South Carolina
-
Kontakt:
- Site Public Contact
- Telefonnummer: 843-792-9321
- E-Mail: hcc-clinical-trials@musc.edu
-
Hauptermittler:
- Jacqueline M. Kraveka
-
Columbia, South Carolina, Vereinigte Staaten, 29203
- Rekrutierung
- Prisma Health Richland Hospital
-
Hauptermittler:
- Stuart L. Cramer
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
Greenville, South Carolina, Vereinigte Staaten, 29605
- Rekrutierung
- BI-LO Charities Children's Cancer Center
-
Hauptermittler:
- Aniket Saha
-
Kontakt:
- Site Public Contact
- Telefonnummer: 864-522-4317
- E-Mail: Kim.Williams3@prismahealth.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Vereinigte Staaten, 57117-5134
- Rekrutierung
- Sanford USD Medical Center - Sioux Falls
-
Kontakt:
- Site Public Contact
- Telefonnummer: 605-312-3320
- E-Mail: OncologyClinicalTrialsSF@SanfordHealth.org
-
Hauptermittler:
- Jordan Fritch-Hanson
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37916
- Rekrutierung
- East Tennessee Childrens Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 865-541-8266
-
Hauptermittler:
- Susan E. Spiller
-
Memphis, Tennessee, Vereinigte Staaten, 38105
- Rekrutierung
- Saint Jude Children's Research Hospital
-
Hauptermittler:
- Sara M. Federico
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-226-4343
- E-Mail: referralinfo@stjude.org
-
Nashville, Tennessee, Vereinigte Staaten, 37232
- Rekrutierung
- Vanderbilt University/Ingram Cancer Center
-
Hauptermittler:
- Daniel J. Benedetti
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-811-8480
-
Nashville, Tennessee, Vereinigte Staaten, 37203
- Rekrutierung
- The Children's Hospital at TriStar Centennial
-
Kontakt:
- Site Public Contact
- Telefonnummer: 615-342-1919
-
Hauptermittler:
- Clinton M. Carroll
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78723
- Rekrutierung
- Dell Children's Medical Center of Central Texas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 512-628-1902
- E-Mail: TXAUS-DL-SFCHemonc.research@ascension.org
-
Hauptermittler:
- Shannon M. Cohn
-
Corpus Christi, Texas, Vereinigte Staaten, 78411
- Rekrutierung
- Driscoll Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 361-694-5311
- E-Mail: Crystal.DeLosSantos@dchstx.org
-
Hauptermittler:
- Nkechi I. Mba
-
Dallas, Texas, Vereinigte Staaten, 75390
- Rekrutierung
- UT Southwestern/Simmons Cancer Center-Dallas
-
Hauptermittler:
- Tanya C. Watt
-
Kontakt:
- Site Public Contact
- Telefonnummer: 214-648-7097
- E-Mail: canceranswerline@UTSouthwestern.edu
-
Dallas, Texas, Vereinigte Staaten, 75230
- Rekrutierung
- Medical City Dallas Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 972-566-5588
-
Hauptermittler:
- Maurizio L. Ghisoli
-
El Paso, Texas, Vereinigte Staaten, 79905
- Rekrutierung
- El Paso Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 915-298-5444
- E-Mail: ranjan.bista@ttuhsc.edu
-
Hauptermittler:
- Benjamin Carcamo
-
Fort Worth, Texas, Vereinigte Staaten, 76104
- Rekrutierung
- Cook Children's Medical Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 682-885-2103
- E-Mail: CookChildrensResearch@cookchildrens.org
-
Hauptermittler:
- Chelsee Greer
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 713-798-1354
- E-Mail: burton@bcm.edu
-
Hauptermittler:
- Jennifer H. Foster
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- UT MD Anderson Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-632-6789
- E-Mail: askmdanderson@mdanderson.org
-
Hauptermittler:
- Najat C. Daw
-
Lubbock, Texas, Vereinigte Staaten, 79410
- Rekrutierung
- Covenant Children's Hospital
-
Hauptermittler:
- Kishor M. Bhende
-
Kontakt:
- Site Public Contact
- Telefonnummer: 806-725-8657
- E-Mail: mbisbee@providence.org
-
Lubbock, Texas, Vereinigte Staaten, 79415
- Rekrutierung
- UMC Cancer Center / UMC Health System
-
Kontakt:
- Site Public Contact
- Telefonnummer: 806-775-8590
-
Hauptermittler:
- Erin K. Barr
-
San Antonio, Texas, Vereinigte Staaten, 78207
- Rekrutierung
- Children's Hospital of San Antonio
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-704-2894
- E-Mail: bridget.medina@christushealth.org
-
Hauptermittler:
- Julie Voeller
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Rekrutierung
- University of Texas Health Science Center at San Antonio
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-450-3800
- E-Mail: phoresearchoffice@uthscsa.edu
-
Hauptermittler:
- Aaron J. Sugalski
-
San Antonio, Texas, Vereinigte Staaten, 78229
- Rekrutierung
- Methodist Children's Hospital of South Texas
-
Kontakt:
- Site Public Contact
- Telefonnummer: 210-575-6240
- E-Mail: Vinod.GidvaniDiaz@hcahealthcare.com
-
Hauptermittler:
- Jose M. Esquilin
-
-
Utah
-
Salt Lake City, Utah, Vereinigte Staaten, 84113
- Rekrutierung
- Primary Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 801-585-5270
-
Hauptermittler:
- Leonora R. Slatnick
-
-
Vermont
-
Burlington, Vermont, Vereinigte Staaten, 05405
- Rekrutierung
- University of Vermont and State Agricultural College
-
Kontakt:
- Site Public Contact
- Telefonnummer: 802-656-8990
- E-Mail: rpo@uvm.edu
-
Hauptermittler:
- Jessica L. Heath
-
-
Virginia
-
Charlottesville, Virginia, Vereinigte Staaten, 22908
- Rekrutierung
- University of Virginia Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 434-243-6303
- E-Mail: uvacancertrials@hscmail.mcc.virginia.edu
-
Hauptermittler:
- Brian C. Belyea
-
Portsmouth, Virginia, Vereinigte Staaten, 23708-2197
- Rekrutierung
- Naval Medical Center - Portsmouth
-
Kontakt:
- Site Public Contact
- Telefonnummer: 757-953-5939
-
Hauptermittler:
- Karin Brockman
-
-
Washington
-
Seattle, Washington, Vereinigte Staaten, 98105
- Rekrutierung
- Seattle Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 866-987-2000
-
Hauptermittler:
- Sarah E. Leary
-
Spokane, Washington, Vereinigte Staaten, 99204
- Rekrutierung
- Providence Sacred Heart Medical Center and Children's Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-228-6618
- E-Mail: HopeBeginsHere@providence.org
-
Hauptermittler:
- Judy L. Felgenhauer
-
Tacoma, Washington, Vereinigte Staaten, 98405
- Rekrutierung
- Mary Bridge Children's Hospital and Health Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 253-403-1461
- E-Mail: research@multicare.org
-
Hauptermittler:
- Robert G. Irwin
-
-
West Virginia
-
Huntington, West Virginia, Vereinigte Staaten, 25701
- Rekrutierung
- Edwards Comprehensive Cancer Center
-
Hauptermittler:
- Mark A. Ranalli
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-399-6566
- E-Mail: Christina.Cole@chhi.org
-
Morgantown, West Virginia, Vereinigte Staaten, 26506
- Rekrutierung
- West Virginia University Healthcare
-
Kontakt:
- Site Public Contact
- Telefonnummer: 304-293-7374
- E-Mail: cancertrialsinfo@hsc.wvu.edu
-
Hauptermittler:
- Ashley E. Meyer
-
-
Wisconsin
-
Green Bay, Wisconsin, Vereinigte Staaten, 54301
- Suspendiert
- Saint Vincent Hospital Cancer Center Green Bay
-
Madison, Wisconsin, Vereinigte Staaten, 53792
- Rekrutierung
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-622-8922
- E-Mail: clinicaltrials@cancer.wisc.edu
-
Hauptermittler:
- Margo L. Hoover-Regan
-
Marshfield, Wisconsin, Vereinigte Staaten, 54449
- Rekrutierung
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-Mail: oncology.clinical.trials@marshfieldresearch.org
-
Hauptermittler:
- Michelle A. Manalang
-
Milwaukee, Wisconsin, Vereinigte Staaten, 53226
- Rekrutierung
- Children's Hospital of Wisconsin
-
Hauptermittler:
- Angela Steineck
-
Kontakt:
- Site Public Contact
- Telefonnummer: 414-955-4727
- E-Mail: MACCCTO@mcw.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Patients must be enrolled on APEC14B1 and have consented to testing through the Molecular Characterization Initiative (MCI), prior to enrollment on ANBL2131
-
≤ 30 years at the time of initial diagnosis with high-risk disease
-
* Must have a diagnosis of neuroblastoma (NBL) or ganglioneuroblastoma (nodular) verified by tumor pathology analysis or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamines
-
Newly diagnosed, high risk neuroblastoma (HRNBL) defined as one of the following:
- Any age with International Neuroblastoma Risk Group (INRG) Stage L2, MS, or M and MYCN amplification
- Age ≥ 547 days and INRG stage M regardless of biologic features (clinical MYCN testing not required prior to enrollment)
- Any age initially diagnosed with INRG Stage L1 MYCN amplified NBL who have progressed to stage M without systemic chemotherapy
- Age ≥ 547 days of age initially diagnosed with INRG Stage L1, L2, or MS who have progressed to stage M without systemic chemotherapy (clinical MYCN testing not required prior to enrollment)
-
-
Patients must have a body surface area (BSA) ≥ 0.25 m^2
-
No prior anti-cancer therapy except as outlined below:
- Patients initially recognized to have high-risk disease treated with topotecan/cyclophosphamide initiated on an emergent basis and within allowed timing, and with consent
- Patients observed or treated with a single cycle of chemotherapy per a low or intermediate risk neuroblastoma regimen (e.g., as per ANBL0531, ANBL1232 or similar) for what initially appeared to be non-high-risk disease but subsequently found to meet the criteria
- Patients who received localized emergency radiation to sites of life threatening or function-threatening disease prior to or immediately after establishment of the definitive diagnosis
-
Human immunodeficiency virus (HIV) -infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
A serum creatinine based on age/sex as follows:
-
1 month to < 6 months: Male 0.4 mg/dL and female 0.4mg/dL
-
6 months to < 1 year: Male 0.5 mg/dL and female 0.5 mg/dL
-
1 to < 2 years: Male 0.6 mg/dL and female 0.6 mg/dL
-
2 to < 6 years: Male 0.8 mg/dL and female 0.8 mg/dL
-
6 to < 10 years: Male 1 mg/dL and female 1 mg/dL
-
10 to < 13 years: Male 1.2 mg/dL and female 1.2 mg/dL
-
13 to < 16 years: Male 1.5 mg/dL and female 1.4 mg/dL
-
≥ 16 years: Male 1.7 mg/dL and female 1.4 mg/dL
- The threshold creatinine values were derived from the Schwartz formula for estimating glomerular filtration rate (GFR) utilizing child length and stature data published by the Centers for Disease Control (CDC)
-
or a 24-hour urine creatinine clearance ≥ 70 mL/min/1.73 m^2 or
-
or a GFR ≥ 70 mL/min/1.73 m^2. GFR must be performed using direct measurement with a nuclear blood sampling method or direct small molecule clearance method (iothalamate or other molecule per institutional standard)
- Note: Estimated GFR (eGFR) from serum creatinine, cystatin C or other estimates are not acceptable for determining eligibility
-
-
Total bilirubin ≤ 1.5 x upper limit of normal (ULN) for age
-
Serum glutamic pyruvic transaminase (SGPT) (Alanine aminotransferase [ALT]) ≤ 10 x ULN*
- Note: For the purpose of this study, the ULN for SGPT (ALT) has been set to the value of 45 U/L
-
* Shortening fraction of ≥ 27% by echocardiogram, or
- Ejection fraction of ≥ 50% by echocardiogram or radionuclide angiogram
-
Ability to tolerate Peripheral Blood Stem Cell (PBSC) collection:
No known contraindication to PBSC collection. Examples of contraindications might be a weight or size less than the collecting institution finds feasible, or a physical condition that would limit the ability of the child to undergo apheresis catheter placement (if necessary) and/or the apheresis procedure
Exclusion Criteria:
- Patients who are 365-546 days of age with INRG Stage M and MYCN non-amplified NBL, irrespective of additional biologic features
- Patients ≥ 547 days of age with INRG Stage L2, MYCN non-amplified NBL, regardless of additional biologic features
- Patients with known bone marrow failure syndromes
- Patients on chronic immunosuppressive medications (e.g., tacrolimus, cyclosporine, corticosteroids) for reasons other than prevention/treatment of allergic reactions and adrenal replacement therapy are not eligible. Topical and inhaled corticosteroids are acceptable
- Patients with a primary immunodeficiency syndrome who require ongoing immune globulin replacement therapy
- Female patients who are pregnant since fetal toxicities and teratogenic effects have been noted for several of the study drugs. A pregnancy test is required prior to enrollment for female patients of childbearing potential
- Lactating females who plan to breastfeed their infants
- Sexually active patients of reproductive potential who have not agreed to use an effective contraceptive method for the duration of their study participation
- All patients and/or their parents or legal guardians must sign a written informed consent
- All institutional, food and drug administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Arm A (SOC treatment)
See detailed description |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo bone marrow biopsy
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given IV
Andere Namen:
Undergo CT scan
Andere Namen:
Given IV
Andere Namen:
Undergo radiation therapy
Andere Namen:
Undergo blood and urine sample collection
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo FDG PET
Andere Namen:
Undergo stem cell infusion
Andere Namen:
Given PO
Andere Namen:
Undergo apheresis
Andere Namen:
Undergo I-MIBG scan
Andere Namen:
Given PO or via NG or G tube
Andere Namen:
Undergo tumor resection surgery |
|
Experimental: Arm B (Dinutuximab in induction)
See detailed description |
Given IV
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo bone marrow biopsy
Andere Namen:
Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo MRI
Andere Namen:
Undergo ECHO
Andere Namen:
Undergo MUGA
Andere Namen:
Undergo bone marrow aspiration Given IV
Andere Namen:
Undergo CT scan
Andere Namen:
Given IV
Andere Namen:
Undergo radiation therapy
Andere Namen:
Undergo blood and urine sample collection
Andere Namen:
Ancillary studies Given IV
Andere Namen:
Given IV Given IV
Andere Namen:
Given IV
Andere Namen:
Undergo FDG PET
Andere Namen:
Undergo stem cell infusion
Andere Namen:
Given PO
Andere Namen:
Undergo apheresis
Andere Namen:
Undergo I-MIBG scan
Andere Namen:
Given PO or via NG or G tube
Andere Namen:
Undergo tumor resection surgery |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Event free survival (EFS)
Zeitfenster: Up to 3 years
|
EFS time is calculated from time of randomization to Arms A or B to first episode of disease relapse or progression, second malignancy, or death, or until last contact if no event has occurred. |
Up to 3 years
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
End of Induction (EOI) response rate
Zeitfenster: From randomization to end of extended Induction, up to 12 months
|
The response rate will be calculated among all evaluable patients at end of Induction. Responders are defined as patients who achieve a >= partial response per the revised 2017 International Neuroblastoma Response Criteria (INRC) |
From randomization to end of extended Induction, up to 12 months
|
|
Overall survival (OS)
Zeitfenster: Up to 3 years
|
OS time is calculated from time of randomization to Arms A or B until death, or until last contact if patient is alive. |
Up to 3 years
|
|
Incidence of adverse events
Zeitfenster: Up to 2 years
|
The proportion of patients with at least one grade 3 or higher non-hematologic toxicity or grade 4 or higher hematologic toxicity during protocol therapy, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0, will be reported. |
Up to 2 years
|
|
GD2 expression
Zeitfenster: Up to 12 months
|
Dinutuximab binding to pre-therapy patient tumor samples will be measured and categorized as high or low. |
Up to 12 months
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Association between tumor and host factors and outcomes
Zeitfenster: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in Arms A and B to evaluate the relationship between tumor and host factors (including tumor ALK and other somatic mutations, copy-number aberrations, gene fusions, gene expression, and pathogenic germline variants) and chemo-immunotherapy during Induction with outcome. |
Up to 10 years
|
|
Circulating biomarkers and markers of minimal residual disease
Zeitfenster: Up to 10 years
|
Will be assessed by comparing the proportion of patients with detectable vs. non-detectable tumor markers (including circulating tumor deoxyribonucleic acid, circulating free DNA, circulating tumor cells, and immune function profiling) between Arms A and B during and after induction and post-consolidation therapy using chi-squared tests at each individual time point, and Cochran's Q across time points to determine if there is a consistent difference in proportions between arms across time. In addition, the tumor markers will be analyzed as continuous variables using longitudinal data analysis methodology such as mixed effects models or generalized estimating equations as appropriate. |
Up to 10 years
|
|
Patterns of failure
Zeitfenster: Up to 10 years
|
The impact of early or late chemoimmunotherapy during Induction on the probability of the involvement of a specific disease site at first relapse will be evaluated using Fisher's exact test. |
Up to 10 years
|
|
Effect of telomere maintenance mechanisms
Zeitfenster: Up to 10 years
|
A series of univariate and multivariate Cox proportional hazards (for EFS and OS) and logistic regression (for responders vs. non-responders) models will be fit for patients in arms A and B to evaluate the relationship between telomere maintenance mechanism and chemoimmunotherapy during Induction with outcome. Patients will be classified into 3 groups by telomere maintenance mechanism (TMM) based on messenger ribonucleic acid expression of TERT and analysis of telomeric DNA C-circles: telomerase (TERT) positive, alternative of lengthening of telomeres (ALT) positive, or no identified TMM. |
Up to 10 years
|
|
Functional and quality of life outcomes
Zeitfenster: At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
Will descriptively summarize and compare the total Memorial Symptom Assessment Scale scores, total sub-domain scores, and individual symptom scores between patients randomized to receive dinutuximab during Induction (Arm B) to those of patients randomized to standard Induction (Arm A). |
At serial time points during Induction, Extended Induction, Post-Consolidation, and at the end of therapy
|
|
Adequacy of diagnostic biopsy specimens
Zeitfenster: At time of tissue collection
|
Will be evaluated by descriptively comparing the successful delineation of histologic classification, MYCN amplification status, and ALK status via the traditional method of obtaining tissue for diagnosis, open surgical biopsy, versus the less invasive percutaneous core needle biopsy. |
At time of tissue collection
|
|
Associations between family-reported adverse social determinants of health and both clinical outcomes and biology
Zeitfenster: Up to 10 years
|
Kaplan-Meier curves of EFS and OS will be generated and used to calculate 3-year EFS and OS estimates. Associations between social determinants of health (SDOH) and survival outcomes and time to receipt of dinutuximab will be evaluated with univariate and multivariate Cox proportional hazard models. Log-binomial regression will be used to estimate risk ratios and 95% CI for the occurrence of dinutuximab consent to randomization and therapy receipt by SDOH exposure. Effect modification of outcomes as a function of poverty, stratified by race/ethnicity, will be explored. |
Up to 10 years
|
|
Develop and validate deep learning predictors of Induction response (imaging objective)
Zeitfenster: At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
Scans will be given as input to a convolutional neural network trained to predict EOI response. |
At diagnosis, EOI, during Extended Induction, and end of Extended Induction
|
|
Compare institutional versus central determination of overall response, individual response components, and PEIR and GEIR determination (imaging objective)
Zeitfenster: Up to 10 years
|
Will be assessed by calculating the percentage of patients receiving the same EOI institutional and centrally reviewed determination of overall response, individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease), and PEIR and GEIR. In addition, Cohen's kappa will be calculated to evaluate the concordance in each of these response measures. |
Up to 10 years
|
|
Incidence of late toxicities
Zeitfenster: Up to 10 years
|
Will be addressed by calculating the proportion of treated patients with each late effect, including but not limited to impaired organ function, neuropsychiatric toxicity, and secondary malignancy. A 95% confidence interval will be placed on each proportion. |
Up to 10 years
|
|
Reduced dose radiotherapy to the primary site clinical target volume (CTV) in patients with complete response of the primary site at EOI results in comparable local control relative to historical cohorts
Zeitfenster: Up to 10 years
|
The cumulative incidence of local progression (CILP) in patients with complete response of the primary site at EOI and GEIR on this study will be compared to the CILP rate of 11.2±1.8% observed on ANBL0532 using Gray's test. |
Up to 10 years
|
|
Post-transplant complications
Zeitfenster: Up to 100 days post-transplant
|
Will be evaluated by calculating the incidence of endothelial injury complications and non-relapse mortality within 100 days of transplant, transplant-associated thrombotic microangiopathy (TA-TMA), severe TA-TMA, and sinusoidal obstruction syndrome (SOS) on Arms A and B and comparing between arms with a chi-squared test. The impact of TA-TMA occurrence on the timing or exclusion of subsequent therapy and interventions utilized to treat the TA-TMA, and associations with outcomes (EFS and OS) will be assessed. |
Up to 100 days post-transplant
|
|
Associations between end of induction (EOI) response and individual response components
Zeitfenster: Up to 10 years
|
Log-rank tests will be used to explore the association between EOI response (using both the revised INRC and GEIR/PEIR classification) and individual response components (primary tumor, soft tissue and bone metastatic disease, and bone marrow metastatic disease) with outcome (EFS and OS). |
Up to 10 years
|
|
Changes in image-defined risk factors (IDRF)
Zeitfenster: Up to 10 years
|
The proportion of patients in the analytic cohort for whom each particular IDRF and also the presence of any IDRF is absent prior to surgical resection will be computed. McNemar's test for paired observations will be applied to determine whether there is a difference in the proportion of each IDRF and any IDRF present before and after initial therapy, and conditional logistic regression will be used to compare between treatment arms A and B. The IDRF status after initial therapy and whether there has been a change from diagnosis will be associated with surgical outcome (complete vs. incomplete resection, presence or absence of surgical complications) using chi-squared tests, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel test. The association of IDRF status with presence or absence of local failure after primary tumor resection will also be evaluated using a chi-squared test, and compared between treatment arms A and B with the Cochran-Mantel-Haenszel. |
Up to 10 years
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Sara M Federico, Children's Oncology Group
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
- Neubildungen
- Neubildungen nach histologischem Typ
- Neubildungen, Drüsen und Epithelien
- Neubildungen, Neuroepithel
- Neuroektodermale Tumoren
- Neoplasmen, Keimzelle und Embryonal
- Neubildungen, Nervengewebe
- Neuroektodermale Tumore, primitiv, peripher
- Neuroektodermale Tumore, primitiv
- Neuroblastom
- Ganglioneuroblastom
- Organisation und Verwaltung
- Verwaltung des Gesundheitswesens
- Aminosäuren, Peptide und Proteine
- Organische Chemikalien
- Heterocyclische Verbindungen, 1-Ring
- Heterocyclische Verbindungen
- Heterocyclische Verbindungen, 2-Ring
- Heterocyclische Verbindungen, Fusionsring
- Untersuchungstechniken
- Therapeutika
- Klinische Labortechniken
- Diagnosetechniken und Verfahren
- Diagnose
- Chirurgische Eingriffe, operativ
- Azolen
- Zytologische Techniken
- Zytodiagnose
- Retinoide
- Carotinoide
- Polyene
- Alkene
- Kohlenwasserstoffe, acyclisch
- Kohlenwasserstoffe
- Cyclohexene
- Cyclohexane
- Cycloparaffine
- Kohlenwasserstoffe, alicyclisch
- Kohlenwasserstoffe, zyklisch
- Terpene
- Pigmente, biologisch
- Biologische Faktoren
- Kohlenhydrate
- Physikalische Phänomene
- Camptothecin
- Alkaloide
- Podophyllotoxin
- Tetrahydronaphthalene
- Naphthenes
- Polycyclische aromatische Kohlenwasserstoffe
- Kohlenwasserstoffe, aromatisch
- Polycyclische Verbindungen
- Glucoside
- Glykoside
- Dacarbazin
- Triazenes
- Imidazoles
- Transplantation
- Indolen
- Anorganische Chemikalien
- Chlorverbindungen
- Stickstoffverbindungen
- Koordinationskomplexe
- Aminosäuren
- Elemente
- Metalle
- Diagnosetechniken, chirurgisch
- Chemie -Techniken, analytisch
- Spektrumanalyse
- Phosphoramid -Senf
- Stickstoffsenfverbindungen
- Senfverbindungen
- Kohlenwasserstoffe, halogeniert
- Phosphoramide
- Organophosphorverbindungen
- Metalle, schwer
- Vinca -Alkaloide
- Secologanin Tryptaminalkaloide
- Indolalkaloide
- Indolizidine
- Indoliziner
- Anthracyclines
- Naphthatene
- Aminoglykoside
- Platinverbindungen
- Daunorubicin
- Übergangselemente
- Zelltransplantation
- Zell- und Gewebe-basierte Therapie
- Biologische Therapie
- Zytapherese
- Entfernung von Blutkomponenten
- Verfahren zur Reduzierung von Leukozyten
- Zelltrennung
- Phenylalanin
- Aminosäuren, aromatisch
- Aminosäuren, zyklisch
- Krankenhausverwaltung
- Verwaltung der Gesundheitseinrichtung
- Triethyleneposphoramid
- Aziridine
- Azirinen
- Urologische chirurgische Verfahren
- Urogenitale chirurgische Eingriffe
- Temozolomid
- Irinotecan
- Cyclophosphamid
- Melphalan
- Etoposid
- Carboplatin
- Doxorubicin
- Vincristin
- Cisplatin
- Isotretinoin
- Thiotepa
- Topotecan
- 1,2-Diaminocyclohexanplatin-II-Citrat
- Strahlentherapie
- Strahlung
- Biopsie
- Handhabung von Proben
- Magnetresonanzspektroskopie
- Platin
- Dinutuximab
- Stammzelltransplantation
- Hämatopoetische Stammzelltransplantation
- Leukaphherese
- Abteilung für Nuklearmedizin, Krankenhaus
- Transurethrale Resektion der Blase
Andere Studien-ID-Nummern
- NCI-2023-08530
- U10CA180886 (US NIH Stipendium/Vertrag)
- NCI-2023-08530 (Registrierungskennung: CTRP (Clinical Trial Reporting Program))
- ANBL2131 (Andere Kennung: CTEP)
- ANBL2131 (Andere Kennung: Children's Oncology Group)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
"NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page."
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .